Otro
Simvastatin therapy in cyclosporine A-induced alveolar bone loss in rats
Registro en:
Journal of Periodontal Research. Malden: Wiley-blackwell Publishing, Inc, v. 44, n. 4, p. 479-488, 2009.
0022-3484
10.1111/j.1600-0765.2008.01143.x
WOS:000267426900008
Autor
Nassar, P. O.
Nassar, C. A.
Guimaraes, M. R.
Aquino, S. G.
Andia, D. C.
Muscara, M. N.
Spolidório, Denise Madalena Palomari
Rossa, C.
Spolidório, Luis Carlos
Resumen
Background and Objective:Cyclosporine A treatment is important in the therapy of a number of medical conditions; however, alveolar bone loss is an important negative side-effect of this drug. As such, we evaluated whether concomitant administration of simvastatin would minimize cyclosporine A-associated alveolar bone loss in rats subjected, or not, to experimental periodontal disease.Material and Methods:Groups of 10 rats each were treated with cyclosporine A (10 mg/kg/day), simvastatin (20 mg/kg/day), cyclosporine A and simvastatin concurrently (cyclosporine A/simvastatin) or vehicle for 30 days. Four other groups of 10 rats each received a cotton ligature around the lower first molar and were treated similarly with cyclosporine A, simvastatin, cyclosporine A/simvastatin or vehicle. Calcium (Ca(2+)), phosphorus and alkaline phosphatase levels were evaluated in serum. Expression levels of interleukin-1 beta, prostaglandin E(2) and inducible nitric oxide synthase were evaluated in the gingivomucosal tissues. Bone volume and numbers of osteoblasts and osteoclasts were also analyzed.Results:Treatment with cyclosporine A in rats, with or without ligature, was associated with bone loss, represented by a lower bone volume and an increase in the number of osteoclasts. Treatment with cyclosporine A was associated with bone resorption, whereas simvastatin treatment improved cyclosporine A-associated alveolar bone loss in all parameters studied. In addition, simvastatin, in the presence of inflammation, can act as an anti-inflammatory agent.Conclusion:This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1 beta and prostaglandin E(2) production. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)